Study Summary
This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）BIOLOGICAL
CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.
Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.
Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of Nanchang University; | Nanchang | Jiangxi | China |
| Fudan University Shanghai Cancer Center | Shanghai | Shanghai Municipality | China |